Investors in Capricor Therapeutics Urged to Act Before Class Action Deadline #United_States #San_Francisco #Hagens_Berman #deramiocel #Capricor_Therapeutics

Investors in Capricor Therapeutics Urged to Act Before Class Action Deadline #United_States #San_Francisco #Hagens_Berman #deramiocel #Capricor_Therapeutics
Investors of Capricor Therapeutics Have Class Action Lawsuit Opportunity Before September Deadline #USA #San_Francisco #Hagens_Berman #deramiocel #Capricor_Therapeutics
Capricor Therapeutics Faces Class Action Over Alleged Securities Fraud in Deramiocel Clinical Data #USA #California #Bleichmar_Fonti #deramiocel #Capricor_Therapeutics
Capricor Therapeutics Faces FDA Review Delay as Investors Prepare for Class Action Deadline #United_States #San_Francisco #deramiocel #Capricor_Therapeutics #FDA_Review
Capricor Therapeutics Investors Have Until September 28 for Class Action Participation #United_States #Class_Action #San_Francisco #deramiocel #Capricor_Therapeutics
Hagens Berman Informs Investors of FDA Review Extension for Capricor Therapeutics Amid Legal Proceedings #United_States #San_Francisco #Hagens_Berman #deramiocel #Capricor_Therapeutics
Capricor Therapeutics Faces Class Action Lawsuit After Major Stock Plummet Linked to Clinical Data Issues #United_States #California #Securities_Fraud #deramiocel #Capricor_Therapeutics